Comparative study of four different assays for the detection of binding                 antibodies against interferon-β

Gneiss, Claudia; Brügger, Melanie; Millonig, Alban; Fogdell‐Hahn, Anna; Rudzki, Dagmar; Hillert, Jan; Berger, Thomas; Reindl, Markus; Deisenhammer, Florian

doi:10.1177/1352458508089228

Cited by 18 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BAb cut-off titer might also vary, depending upon the assay used. Although previous studies found fair inter-and intra-assay variability in terms of BAb frequency, 19,34 there are some hints that BAb titers differ between the different immunoassays. 19 The chosen time point for blood collection of 4-12 hours after the last IFN-b injection seemed appropriate, as previous studies show that different IFN-b-gene products are already induced after 3 hours and peak around 12 hours.…”

Section: Discussionmentioning

confidence: 81%

“…Although previous studies found fair inter-and intra-assay variability in terms of BAb frequency, 19,34 there are some hints that BAb titers differ between the different immunoassays. 19 The chosen time point for blood collection of 4-12 hours after the last IFN-b injection seemed appropriate, as previous studies show that different IFN-b-gene products are already induced after 3 hours and peak around 12 hours. 12,20,28 We want to stress that this investigation was not intended to study the impact of anti-IFN-b antibodies on clinical outcome parameters.…”

Section: Discussionmentioning

confidence: 81%

“…We measured BAbs by direct enzyme-linked immunosorbent assay (ELISA), as previously described, 19 at the time points designated BL1, Mo3 and Mo12. For details on the sample matrix, see the Supplementary Material.…”

Section: Bab Assaymentioning

confidence: 99%

See 2 more Smart Citations

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Measurement of BAbs by Western blotting [Gneiss et al 2008] involves the separation of the IFNβ by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer onto a nitrocellulose membrane. Membrane strips are incubated with diluted patient serum, a positive control (mouse anti-IFNβ) and a negative control.…”

Section: Testing Binding Antibodies and Neutralizing Antibodies In Thmentioning

confidence: 99%

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

Creeke

Farrell

2012

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Biopharmaceuticals are drugs which are based on naturally occurring proteins (antibodies, receptors, cytokines, enzymes, toxins), nucleic acids (DNA, RNA) or attenuated microorganisms. Immunogenicity of these agents has been commonly described and refers to a specific antidrug antibody response. Such immunogenicity represents a major factor impairing the efficacy of biopharmaceuticals due to biopharmaceutical neutralization. Indeed, clinical experience has shown that induction of antidrug antibodies is associated with a loss of response to biopharmaceuticals and also with hypersensitivity reactions. The first disease-specific agent licensed to treat multiple sclerosis (MS) was interferon-β (IFNβ). In its various preparations, it remains the most commonly used first-line agent. The occurrence of antidrug antibodies has been extensively researched in MS, particularly in relation to IFNβ. However, much controversy remains regarding the significance of these antibodies and incorporation of testing into clinical practice. Between 2% and 45% of people treated with IFNβ will develop neutralizing antibodies, and this is dependent on the specific drug and dosing regimen. The aim of this review is to discuss the use of IFNβ in MS, the biological and clinical relevance of anti-IFNβ antibodies (binding and neutralizing antibodies), the incorporation of testing in clinical practice and ongoing research in the field.

show abstract

“…The most commonly used method for measuring of BAbs is ELISA [10,17], particularly capture ELISA, which correlates better with NAb titers than does direct ELISA [18]. In general, ELISA titers correlate only weakly with NAb titers, but BAb-negative samples measured by ELISA reliably predict NAb-negativity [19].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability

et al. 2015

View full text Add to dashboard Cite

BackgroundNeutralizing antibodies (NAb) to interferon-beta (IFN-β) are associated with reduced bioactivity and efficacy of IFN-β in multiple sclerosis (MS). The myxovirus resistance protein A (MxA) gene expression is one of the most appropriate markers of biological activity of exogenous IFN-β. We hypothesized that therapeutic plasma exchange (TPE) can restore the ability of IFN-β to induce the MxA mRNA expression and that maintenance plasmapheresis can sustain the bioavailability of IFN-β.Material/MethodsEligible patients underwent 4 primary separate plasma exchange sessions. After the induction TPE sessions, they were transferred to maintenance plasmapheresis. Bioactivity of IFN-β was expressed as in vivo MxA mRNA induction in whole blood using RT-qPCR.ResultsSix patients with low IFN-β bioavailability detected by the MxA mRNA response were included. Four patients became biological responders after induction plasmapheresis. In 2 patients an increase of MxA mRNA expression was found, but the values persisted below the cut-off and the patients remained as “poor biological responders”. The effect of maintenance plasmapheresis was transient: MxA mRNA expression values reverted to the baseline levels after 1–2 months.ConclusionsTherapeutic plasma exchange is able to restore the bioavailability of IFN-β in the majority of studied patients, but the effect of TPE on the IFN-β bioavailability was transient.

show abstract

Comparative study of four different assays for the detection of binding antibodies against interferon-β

Abstract: We conclude that the cELISA seems to be most suitable for NAB screening, but BAB titers cannot reliably predict NAB titers.

Cited by 18 publications

References 27 publications

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability

Contact Info

Product

Resources

About